ADVANCED TECHNOLOGY **FOR BETTER OUTCOMES.**

Now approved for your patients, ages 7 and older.[1]

MiniMed™ 670G System with SmartGuard™ Technology



#1
PRESCRIBED PUMP BRAND

"Since Jack has gotten the MiniMed™ 670G my wife and I can sleep through the night knowing he will be okay and safe."

– Brendan,
father of Jack, 8-year old
with type 1 diabetes



ASCENSIA Diabetes Care Medtronic

PROACTIVE DIABETES MANAGEMENT.

Patients have different insulin requirements throughout the day. No two days are the same, why should your patients' insulin dose be?

The MiniMed™ 670G system – the world's first hybrid closed loop (HCL) system that self-adjusts basal insulin delivery automatically.[∞]

Guardian™ Sensor 3 and Guardian™ Link 3 transmitter.

- Our **most accurate** sensor to-date.
- A **smart diagnostic chip** continuously monitors sensor health to optimize performance and ensure reliability
- **80% smaller** than our previous sensors, more flexible and comfortable to wear

CONTOUR®NEXT LINK 2.4 Meter.

Designed for easy and accurate[1] wireless CGM calibration and insulin dosing.[‡,§]

ASCENSIA Diabetes Care

Unlike other pumps

Includes two levels of SmartGuard™ automation:

- **Auto Mode,** continuously adjusts basal insulin every 5 minutes based on your patients needs.[∞]
- **Manual Mode with Suspend before low** which automatically suspends and resumes insulin delivery to help protect against lows.[‖]

CareLink™ software for diabetes management.

Clearer insights and easier access with a web-based software and re-designed reports leading to more productive patient conversations.

3 OUT OF 4

SEVERE HYPOGLYCEMIA EVENTS IN CHILDREN OCCUR AT NIGHT.[2]



STRONG CLINICAL PERFORMANCE
seen in the pediatric pivotal trial[3]

STUDY SHOWED

71%

TIME SPENT IN TARGET RANGE (70-180 mg/dL) OVERNIGHT

PATIENTS EXPERIENCED

51%

REDUCTION IN LOWS OVERNIGHT (<70mg/dL)

WITH THE MINIMED™ 670G SYSTEM, CHILDREN SPENT

98%

OF NIGHT TIME >70mg/dL

ZERO

EPISODES OF DKA & SEVERE HYPOGLYCEMIA
IN 10,602 PATIENT DAYS WHILE IN AUTO MODE

SIMPLIFYING THERAPY ADJUSTMENTS WITH AUTO MODE.

TRADITIONAL PUMP THERAPY

1. Multiple Basal Rates
2. Insulin Sensitivity Factor
3. Target Range
4. Insulin to Carb Ratio
5. Active Insulin Time

VS

MINIMED™ 670G SYSTEM IN AUTO MODE

1. Insulin to Carb Ratio
2. Active Insulin Time

To find out more visit professional.medtronicdiabetes.com/peds

∞ Refers to AutoMode. Some interaction required. Individual results may vary. *Refers to SmartGuard™ Auto Mode feature; The MiniMed™ 670G System can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. Based on clinical study data in pivotal trial. Individual results may vary. **An A1C goal of 7.5% is recommended across all pediatric age-groups. † Based on Guardian™ Sensor 3 glucose values. ‡Ascensia Data on File. ¥The pump is protected against the effects of continuous immersion iwhen reservoir and tubing are properly inserted, the pump is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for details.

| WARNING (ages 7-13): The low sensor glucose alert functionality is distinct from the automated insulin dosing function of the MiniMed™ 670G system. When used in Auto Mode, the MiniMed™ 670G system has been shown to be safe and effective for its intended use in this population. However, do not rely solely on the use of a low sensor glucose (SG) value for "Alert on Low" or "Alert before Low" for alerts set at 50 mg/dL and 60 mg/dL. A low sensor glucose alert may not reflect the user's true blood glucose at these levels or may not alert. Do not ignore symptoms of low glucose. Always confirm your sensor glucose readings with your blood glucose meter and treat according to the recommendations of your healthcare professional. Solely relying on these sensor glucose alerts and readings for treatment decisions could result in missing severe hypoglycemia (low blood glucose) events.

|| WARNING: Suspend before low and Suspend on low are not intended to be a treatment for low blood glucose. Having insulin suspended when glucose is low may not bring your blood glucose back to your target range for several hours. In that case, you run the risk of hypoglycemia. Always confirm your blood glucose readings with your BG meter and treat according to the recommendations of your healthcare professional.

1. Bailey T, Wallace JF, Greene, C et al. Accuracy and user performance evaluation of the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system. *Clin Chim Acta.* 2015; 448:139 -145. **2.** Ahmet, A. Dagenais S, Barrowman NJ, Collins CJ, Lawson ML. et al. Prevalence of nocturnal hypoglycemia in pediatric type 1 diabetes: a pilot study using continuous glucose monitoring. *J Pediatrics.* 2011, 159:2, 297-302. **3.** Data on file. 10,602 patient days. Pediatric pivotal trial.

IMPORTANT SAFETY INFORMATION: MINIMED™ 670G SYSTEM

The MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below, or is predicted to fall below, predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site testing (palm) or from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the "Always" send mode. Only use rapid acting U100 insulin with this system. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. Indicated for type 1 patients 7 and over.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore, this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day, because the device requires a minimum of 8 units per day to operate safely. For complete details, including product and important safety information concerning the system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
Please visit www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.
CONTOUR NEXT LINK 2.4 is the only meter FDA-approved for use with the MiniMed™ 670G system.

ASCENSIA Diabetes Care

Medtronic